Table 3 SHR erythrocyte monounsaturated fatty acid composition (%total fatty acids) following the consumption of diets with a 25:1 ω-6/ω-3 FAR for 6 weeks^§

Undecenoic

C11:1

nd

nd

nd

nd

nd

Dodecenoic

C12:1

nd

nd

nd

nd

nd

Tridecanoic

C13:1

nd

nd

nd

nd

nd

Myristoleic

C14:1n5

nd

nd

nd

nd

nd

Pentadecenoic

C15:1n5

0.58 ± 0.08^a

0.04 ± 0.00^b

0.06 ± 0.00^b

0.06 ± 0.01^b

0.06 ± 0.00^b

Palmitoleic

C16:1n7

0.28 ± 0.05^a

0.14 ± 0.01^b

0.16 ± 0.01^b

0.15 ± 0.02^b

0.10 ± 0.02^b

Palmitelaidic

C16:1n7t

0.43 ± 0.04^a

0.41 ± 0.05^a

0.35 ± 0.05^a

0.37 ± 0.04^a

0.56 ± 0.03^b

Heptadecenoic

C17:1n7

nd

nd

nd

nd

nd

Elaidic

C18:1n9t

nd

nd

nd

nd

nd

Vaccenic

C18:1n11c

nd

nd

nd

nd

nd

Trans-vaccenic

C18:1n7t

nd

nd

nd

nd

nd

Oleic

C18:1n9c

5.60 ± 0.61^a

9.41 ± 0.33^c

8.56 ± 0.35^bc

8.55 ± 0.25^bc

7.76 ± 0.23^b

Cis-vaccenic

C18:1n7c

1.30 ± 0.17^a

1.88 ± 0.08^b

1.71 ± 0.07^b

1.78 ± 0.06^b

2.31 ± 0.09^c

cis-5 Eicosenoic

C20:1n15

nd

0.31 ± 0.04

nd

nd

nd

cis-8-Eicosenoic

C20:1n12

nd

0.26 ± 0.03

nd

nd

nd

Eicosenoic

C20:1n9

0.07 ± 0.00^a

0.26 ± 0.03^b

0.23 ± 0.04^b

0.19 ± 0.03^ab

0.22 ± 0.02^b

Erucic

C22:1n9

nd

nd

nd

nd

nd

Nervonic

C24:1n9

0.90 ± 0.20^a

2.38 ± 0.23^b

2.03 ± 0.19^b

2.61 ± 0.41^b

4.08 ± 0.40^c

Total MUFAs

9.09 ± 1.01 ^a

15.10 ± 0.25 ^c

13.11 ± 0.35 ^b

13.64 ± 0.39 ^bc

14.98 ± 0.70 ^c